ORGANIC LETTERS

2006
Vol. 8, No. 13
2811−2813

Synthesis and Molecular Recognition of Phosphatidylinositol-3-methylenephosphate

Joanna Gajewiak,[†] Yong Xu,[†] Stephanie A. Lee,[‡] Tatiana G. Kutateladze,[‡] and Glenn D. Prestwich*,[†]

Department of Medicinal Chemistry, The University of Utah, 419 Wakara Way, Suite 205, Salt Lake City, Utah 84108-1257, and Department of Pharmacology, University of Colorado Health Sciences Center, Aurora, Colorado 80045

glenn.prestwich@hsc.utah.edu

Received April 13, 2006

ABSTRACT



myo-inositol PtdIns(3)MP

Phosphatidylinositol-3-phosphate (PtdIns(3)P) is a spatial regulator of vesicular trafficking and other vital cellular processes. We describe the asymmetric total synthesis of a metabolically stabilized analogue, phosphatidylinositol-3-methylenephosphate (PtdIns(3)MP) from a differentially protected *myo*-inositol. NMR studies of PtdIns(3)MP bound to the ^{15}N-labeled FYVE domain showed significant ^{1}H and ^{15}N chemical shift changes relative to the unliganded protein.

Phosphoinositide (PtdInsP_n) signaling networks are dynamically modulated by proteins with lipid recognition motifs as well as kinase, phosphatase, and phospholipase enzymatic activities. In particular, the 3-phosphorylated PtdInsP_n lipids have been implicated as activators of protein kinase C isoforms and are messengers in cellular signal cascades pertinent to inflammation, cell proliferation, transformation, protein kinesis, and cytoskeletal assembly.[1−3] PtdIns(3)P is produced by the action of phosphoinositide-3-kinase (PI 3-K)[1,4] on PtdIns, and its interactions with cognate binding proteins, kinase, and phosphatases are important in cell physiology. PtdIns(3)P specifically binds FYVE domains[5−7] and is involved in phagocytosis,[8] membrane trafficking, and protein sorting.[9] PX domains also recognize PtdIns(3)P, and spatiotemporal changes mediate important aspects of cell respiration.[10] The myotubularin-related (MTMR) protein family[11] is comprised of PtdIns(3)P phosphatases that contribute to lipid remodeling and are mutated in genetic diseases.[12]

To gain deeper insight into these biological pathways, selective reagents that can interfere with ligand binding, inhibit enzyme activity, and activate protein-mediated lipid signaling are needed.[13] We recently described a general approach to the synthesis of methylphosphonate, (monofluoromethyl)phosphonate, and phosphorothioate analogues

* To whom correspondence should be addressed. Phone: +1-801-585-9051. Fax: +1-801-585-9053.
† The University of Utah.
‡ The University of Colorado Health Sciences Center.

(1) Vanhaesebroeck, B.; Leevers, S. J.; Ahmadi, K.; Timms, J.; Katso, R.; Driscoll, P. C.; Woscholski, R.; Parker, P. J.; Waterfield, M. D. *Annu. Rev. Biochem.* **2001**, *70*, 535−602.
(2) Yin, H. L.; Janmey, P. A. *Annu. Rev. Physiol.* **2003**, *65*, 761−789.
(3) Wymann, M. P.; Bjorklof, K.; Calvez, R.; Finan, P.; Thomas, M.; Trifilieff, A.; Barbier, M.; Altruda, F.; Hirsch, E.; Laffargue, M. *Biochem. Soc. Trans.* **2003**, *31*, 275−280.
(4) Anderson, K. E.; Jackson, S. P. *Int. J. Biochem. Cell Biol.* **2003**, *35*, 1028−1033.
(5) Kutateladze, T.; Ogburn, K.; Watson, W.; de Beer, T.; Emr, S.; Burd, C.; Overduin, M. *Mol. Cell* **1999**, *3*, 805−811.
(6) Gaullier, J. M.; Simonsen, A.; D'Arrigo, A.; Bremnes, B.; Stenmark, H.; Aasland, R. *Nature* **1998**, *394*, 432−433.
(7) Kutateladze, T. *BBA − Mol. Cell Biol. Lipids* **2006**, in press.
(8) Gillooly, D. J.; Simonsen, A.; Stenmark, H. *J. Cell Biol.* **2001**, *155*, 15−17.
(9) Petiot, A.; Faure, J.; Stenmark, H.; Gruenberg, J. *J. Cell Biol.* **2003**, *162*, 971−979.
(10) Sato, T.; Overduin, M.; Emr, S. D. *Science* **2001**, *294*, 1881−1885.
(11) Wishart, M. J.; Dixon, J. E. *Trends Cell Biol.* **2002**, *12*, 579−585.
(12) Laporte, J.; Bedez, F.; Bolino, A.; Mandel, J. L. *Hum. Mol. Genet.* **2003**, *12*, R285−R292.
(13) Prestwich, G. D. *Chem. Biol.* **2004**, *11*, 619−637.

10.1021/ol060903i CCC: $33.50
Published on Web 05/24/2006

of PtdIns(3)P.[14] These metabolically stabilized ligands were recognized by ^{15}N-labeled FYVE and PX domains and were also substrates for PIKfyve, a 5-kinase required for the formation of multivesicular bodies. We now introduce a modified synthetic route that provides access to a stabilized methylenephosphonate analogue, PtdIns(3)MP, which retains the inositol 3-oxygen as well as the dianionic headgroup. In this modification, a methylene bridge was inserted between the oxygen of the inositol moiety and the phosphate headgroup. A similar approach was also used to generate alkoxymethylene phosphonate-containing geranylgeranyl protein transferase inhibitors[15] and antiviral drugs,[16] including anti-HIV phosphorylated nucleoside analogues.[17,18] We have also used this approach to synthesize potent analogues of lysophosphatidic acid and phosphatidic acid, and these results will be presented in due course. Herein, we describe the asymmetric total synthesis of the methylenephosphonate analogue of PtdIns(3)P, and we illustrate the binding of PtdIns(3)MP to the FYVE domain.

The synthetic strategy employed the simple and elegant protection scheme of Bruzik,[19] in which the 1-position of *myo*-inositol (**1**) was silylated with the TBDPS group, the phosphomonoester 3-position was protected as a benzoate group, and all remaining hydroxyl groups were protected as methoxymethyl (MOM) ethers. Thus, 1-*O*-(*tert*-butyl-diphenylsilyl)-2,4,5,6-*O*-tetrakis(methoxymethylene)-*myo*-inositol (**2**) was synthesized from *myo*-inositol in six steps. Installation of the methylenephosphonate moiety required the preparation (Scheme 1) of dimethyl phosphonomethyltriflate

Scheme 1. Synthesis of Dimethyl Phosphonomethyltriflate (**5**)



3 **4** **5**

(**5**) following the literature route.[20,21] Reaction of paraformaldehyde with trimethyl phosphite gave hydroxymethyl phosphonate **4**, which was converted to triflate **5** using 2,6-lutidine as the base and was employed without further purification.

The alkoxide of protected inositide **2** (*n*-BuLi,[15] −78 °C) was alkylated with triflate **5** in 64% yield (Scheme 2). Use of NaH or *t*-BuOK as the base did not significantly improve the yield and resulted in greater decomposition of the starting material. The TBDPS group was removed by treating intermediate **6** with *n*-Bu_4F. The resulting alcohol **7** was coupled with the dibutanoylglyceryl phosphoramidite[14] in the presence of 1*H*-tetrazole, followed by mild oxidation with *n*-$BuNIO_4$[14] to give fully protected PtdIns(3)MP (**8**). The removal of phosphate and hydroxyl protecting groups of **8** was accomplished under strictly anhydrous conditions with 20 equiv of fresh TMSBr (CH_2Cl_2, room temperature, 1 h). After concentration in vacuo, the residue was dissolved in 90% aq CH_3OH and stirred for 40 min to hydrolyze the silyl phosphate esters. We found that under these conditions not only were the phosphates deprotected but also all MOM groups were removed. After complete evaporation of the organic solvent in vacuo, the crude compound was dissolved in water and passed through a short column of acidic Dowex ion-exchange resin to yield the final product in >98% purity.

In endosomal membranes, PtdIns(3)P is specifically recognized by a number of protein binding partners including FYVE and PX domains. We next investigated the interactions of human EEA1 FYVE and yeast Vam7 PX domains with PtdIns(3)MP by NMR spectroscopy. Significant changes were observed in ^{1}H and ^{15}N resonances in the FYVE domain when titrating in dibutanoyl PtdIns(3)MP (**9**) (Figure 1a). These perturbations were of reduced magnitude but paralleled the chemical shift changes apparent in the complex of the FYVE domain with dibutanoyl-PtdIns(3)P (Figure 1b). Thus, the PtdIns(3)MP analogue and native lipid are accommodated by the same binding pocket consisting of four Arg and two His residues of the FYVE domain. On the basis of ^{1}H and ^{15}N chemical shift changes, the FYVE domain affinity for PtdIns(3)MP was calculated to be 3.8 ± 0.5 mM (see supplementary Figure 2 in Supporting Information). To put this in perspective, the local concentration of PtdIns(3)MP

Scheme 2. Synthesis of PtdIns(3)MP (**9**)



1 **2** **6** **7**

9, PtdIns(3)MP **8**



Figure 1. Binding of PtdIns(3)P and PtdIns(3)MP to the FYVE domain. ^{1}H-^{15}N heteronuclear single-quantum coherence (HSQC) NMR spectra of the 0.2 mM EEA1 FYVE domain before and after addition of (a) dibutanoyl-PtdIns(3)MP (**9**) and (b) dibutanoyl-PtdIns(3)P.

in early endosomal membranes is quite high (~200 μM)[22] and the FYVE−dibutanoyl-PtdIns(3)P affinity is 135 μM under similar experimental conditions.[23] A similar experiment with the PX domain showed a much weaker binding without significant chemical shift changes. Addition of up to 11.3 mM (57-fold excess) PtdIns(3)MP to a 0.2 mM PX domain sample induced no noticeable resonance changes. For comparison, the K_d of the PX domain for dibutanoyl-PtdIns(3)P under these conditions is approximately 300 μM.[24] This result may be attributed to the difference in the binding modes for the two complexes. PtdIns(3)P inserts its 3-phosphate between two loops and an α-helix of the PX domain.[25] However, in the case of the FYVE domain, PtdIns(3)P occupies a shallow pocket in a side-on orientation.[26] Apparently, the extended methylenephosphonate group is too bulky to be accommodated in the PX domain binding pocket. Thus, PtdIns(3)MP is the first analogue of PtdIns(3)P that shows discrimination in its protein−ligand interactions, suggesting that it could be useful in selectively perturbing distinct PtdIns(3)P signaling pathways.

Acknowledgment. We thank the NIH (Grant NS 29632 to G.D.P.) and the American Cancer Society (T.G.K.) for financial support of this work.

Supporting Information Available: Experimental details for the synthesis and characterization of new compounds and protocols for the ^{1}H and ^{15}N NMR binding measurements. This material is available free of charge via the Internet at http://pubs.acs.org.

OL060903I

(14) Xu, Y.; Lee, S. A.; Kutateladze, T. G.; Sbrissa, D.; Shisheva, A.; Prestwich, G. D. *J. Am. Chem. Soc.* **2006**, *128*, 885−897.
(15) Minutolo, F.; Antonello, M.; Barontini, S.; Bertini, S.; Betti, L.; Danesi, R.; Gervasi, G.; Giannaccini, G.; Papi, C.; Placanic, G.; Rapposelli, S.; Macchia, M. *Il Farmaco* **2004**, *59*, 887−892.
(16) De Clercq, E.; Holy, A. *Nat. Rev. Drug. Discovery* **2005**, *4*, 928−940.
(17) Jie, L.; Van Aerschot, A.; Balzarini, J.; Janssen, G.; Busson, R.; Hoogmartens, J.; De Clercq, E.; Hardewijn, P. *J. Med. Chem.* **1990**, *33*, 241−245.
(18) Van Aeroschot, A.; Jie, L.; Herdewijn, P. *Tetrahedron Lett.* **1991**, *32*, 1905−1908.
(19) Kubiak, R. J.; Bruzik, K. S. *J. Org. Chem.* **2003**, *68*, 960−968.
(20) Phillion, D. P.; Andrew, S. S. *Tetrahedron Lett.* **1986**, *27*, 1477−1480.
(21) Hamilton, C. J.; Roberts, S. M. *J. Chem. Soc., Perkin Trans. 1* **1999**, 1051−1056.
(22) Stenmark, H.; Gillooly, D. J. *Semin. Cell Dev. Biol.* **2001**, *12*, 193−199.
(23) Lee, S. A.; Eyeson, R.; Cheever, M. L.; Geng, J.; Verkhusha, V. V.; Burd, C.; Overduin, M.; Kutateladze, T. G. *PNAS* **2005**, *102*, 13052−13057.
(24) Cheever, M.; Kutateladze, T.; Overduin, M. Unpublished results.
(25) Bravo, J.; Karathanassis, D.; Pacold, C. M.; Pacold, M.; Ellson, C. D.; Anderson, K. E.; Butler, P.; Lavenir, I.; Perisic, O.; Hawkins, P. T.; Stephens, L.; Williams, R. *Mol. Cells* **2001**, *8*, 829−839.
(26) Kutateladze, T.; Overduin, M. *Science* **2001**, *291*, 1793−1796.